एंडोक्रिनोलॉजी और मेटाबोलिक सिंड्रोम
खुला एक्सेस

अमूर्त

Faster aspart reduces glycemic variability and increases time on target glycemia in type 1 diabetic patients with sensor-augmented insulin pump

Francisco J. Martinez-Martin

Aim: Comparing the effect of Faster Aspart insulin (Fiasp®) with previous insulin analogues (aspart, lispro, glulisine) in type 1 diabetic patients with sensor-augmented pump therapy.

Methods: Patients with the Medtronic MINIMED™ 670G Sensor-Augmented Insulin Pump System (able to automatically adjust background insulin every 5 minutes) were switched from previous insulin to Faster Aspart. Data from the previous 3 months and 3 months afterwards were obtained from the CareLink™ Personal Software and compared by Student’s paired t-test or ANOVA as appropriate. Satisfaction data were obtained by analogic scales. Data are given as Mean±S.D.